Results 121 to 130 of about 1,795 (145)

Emicizumab for hemophilia A without inhibitors

Expert Review of Hematology, 2019
Introduction: Hemophilia A (HA) is an inherited bleeding disorder that, if not properly treated, is associated with debilitating joint damage due to recurrent hemarthroses as well as life-threatening bleeds including intracranial hemorrhage. For decades, the only method to prevent bleeding events was to infuse factor (F) VIII concentrates intravenously
Lorraine Cafuir, Rebecca Kruse-Jarres, Maria Elisa Mancuso, Christine L Kempton   +3 more
openaire   +2 more sources

Emicizumab: A Review in Haemophilia A

Drugs, 2019
Emicizumab (Hemlibra®), a recombinant, humanized, bispecific monoclonal antibody, restores the function of missing activated factor VIII (FVIII) by bridging FIXa and FX to facilitate effective haemostasis in patients with haemophilia A. Subcutaneous emicizumab is approved in several countries, including in the USA and Japan, for the routine prophylaxis
openaire   +2 more sources

Emicizumab in Children with Severe Hemophilia A

Indian Journal of Pediatrics
To assess the effectiveness and tolerability of emicizumab prophylaxis in hemophilia A (HA). Emicizumab is a novel therapeutic drug which is the first and only non-factor replacement agent licensed for use in people with HA.Pediatric patients aged 1 mo to 12 y with severe HA and frequent / life threatening bleeding events, with or without coagulation ...
Usha Rani Thota, Sreelatha Martha, Chaitanya Jyothi Ravula, Nirmala Cherukuri   +3 more
openaire   +2 more sources

Emicizumab for the prevention of bleeds in hemophilia A

Expert Opinion on Biological Therapy, 2019
Introduction: The management of hemophilia A with and without inhibitors is challenging with high treatment burden of prophylactic regimens, musculoskeletal complications, poor treatment compliance, poor venous access and therapies with suboptimal levels.
openaire   +2 more sources

A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A

Journal of Thrombosis and Haemostasis, 2023
Satoshi Higasa
exaly  

Detailed analysis of anti‐emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A

Journal of Thrombosis and Haemostasis, 2021
Ryohei Kawasaki
exaly  

Low immunogenicity of emicizumab in persons with haemophilia A

Haemophilia, 2021
Christophe Schmitt
exaly  

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study

Haemophilia, 2022
Christine Kempton, Anna Kiialainen
exaly  

Functional determination of emicizumab in presence of factor VIII activity

Journal of Thrombosis and Haemostasis, 2023
Bernd Pötzsch, Claudia Klein, Thilo Albert   +2 more
exaly  

Emicizumab prophylaxis: Prospective longitudinal real‐world follow‐up and monitoring

Haemophilia, 2021
Tami Livnat, Ivan Budnik, Assaf Barg
exaly